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ABSTRACT
The clinical diagnosis of Brown–Vialetto–Van
Laere syndrome in this woman with rapidly
progressive pontobulbar palsy led to empirical
high-dose oral riboflavin (1200 mg/day) therapy.
This resulted in a dramatic improvement in her
motor function from being anarthric, dysphagic,
tetraparetic and in ventilatory failure to living
independently with mild dysarthria and distal
limb weakness. DNA sequencing of the SLC52A3
gene found compound heterozygous C-terminus
mutations, V413A1/D461Y, consistent with
recent reports of mutations within the riboflavin
transporter genes (SLC52A2 and SLC52A3) in
this condition. Early diagnosis and empirical
riboflavin therapy can lead to major motor
recovery in this condition, that can be sustained
with long-term maintenance therapy.
BACKGROUND
Brown–Vialetto–Van Laere syndrome
(BVVL) is characterised by progressive
pontobulbar palsy, typically preceded by
sensorineural deafness. In its most severe
form, death occurs in infancy. Milder
phenotypes do occur, but rarely present
past the third decade.1 2 Despite its first
description in 1894, only recently has an
understanding of the genetic and patho-
physiological basis for BVVL opened the
opportunity for therapeutic intervention.
We report the remarkable motor recovery
after riboflavin therapy in a 35-year-old
woman with BVVL syndrome.
CASE PRESENTATION
A 35-year-old British woman presented
with a 6-week history of progressive dys-
phagia, dysphonia, dyspnoea, weight loss,
gait disturbance and arm weakness. On
admission, she could not speak or swallow
and needed the assistance of two people
to walk. She had developed moderate
deafness over many years, but had no
other neurological symptoms. Eight
weeks before admission, she had sepa-
rated from her husband, and the quality
of her diet had significantly deteriorated.
Examination on admission found
broken ocular pursuit in all directions,
bilateral lower motor neurone facial
weakness and absent jaw jerk. Her
hearing was poor bilaterally, her cough
was very weak and palatal elevation was
greatly reduced. Her sternocleidomastoid
and trapezius strength were normal but
her tongue was severely weak, wasted
and fasciculating. Tone was increased at
the right elbow. The upper and lower
limbs were symmetrically weak, with
strength from grade 1–2 distally to grade
3–4 proximally. All limb reflexes were
pathologically brisk with crossed adduc-
tors but both plantar responses were
flexor. Sensation was normal and coord-
ination was difficult to assess with the
severe limb weakness.
INVESTIGATIONS
Arterial blood gases on admission showed
a pH of 7.47, PCO2 of 5.9 kPa (5–6), PO2
of 14.3 kPa (11–12.5) and a bicarbonate
of 30.6 mmol/L (21–28). Her forced vital
capacity was 0.7 L/min and her sniff nasal
inspiratory pressure was reduced at −22
cmH2O (predicted −87). Nasendoscopy
found bilateral vocal cord paralyses.
Nerve conduction studies and central
motor conduction velocities were normal.
Electromyography identified acute
denervation in both tibialis anterior
muscles and chronic denervation findings
in her right first dorsal interosseous
muscle. Audiometry showed a mixed sen-
sorineural and conductive hearing loss
bilaterally. Brainstem auditory evoked
potentials were performed but significant
artefact precluded accurate interpretation.
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onset deafness.6 In contrast, people with SLC52A3
mutations typically present with sensorineural deaf-
ness, followed by pontobulbar palsy, respiratory com-
promise and generalised limb weakness.4 It has been
suggested that the umbrella term of BVVL syndrome
be renamed ‘riboflavin transporter deficiency, types
2 and 3’, to reflect better the underlying patho-
aetiology and distinct clinical phenotypes in this
condition.4 6
Nutritional trigger
The metabolic hallmark of BVVL is abnormal mito-
chondrial fatty acid oxidation and branched-chain
amino acid catabolism. This stems from an acquired
functional riboflavin deficiency, owing to defective ribo-
flavin transporter activity in the gut and/or the brain. It
is possible to detect the biochemical defect by a reduc-
tion in plasma riboflavin, flavin mononucleotide or
flavin adenine dinucleotide concentration, with an
abnormal plasma acylcarnitine profile (selective increase
in short- and medium-chain fatty acid plasma concentra-
tions).8 However, a recent report suggests only 58% of
genetically confirmed patients with BVVL had abnormal
acylcarnitine profiles.3 Additionally, urinary organic
acid profiles can resemble those seen in the multiple
acyl-CoA dehydrogenation defect.
Our patient developed symptoms after an abrupt
change in the quality of her diet 8 weeks before admis-
sion. This very likely triggered motor neuronal dys-
function and degeneration, as her genetic defect left
her vulnerable to a low dietary intake of riboflavin.
Riboflavin therapy in BVVL
The general management of patients with BVVL
includes supportive measures, such as nasogastric tube or
gastrostomy insertion to ensure adequate nutrition, and
non-invasive ventilation to overcome any neurogenic
respiratory compromise. Corticosteroids and immuno-
globulins do not help.2
Riboflavin treatment (reported dose range 7–60 mg/kg/
day) can normalise the metabolic abnormalities
detected in BVVL and lead to clinical stabilisation and
improvement in most people.3 4 9 10 Currently there is
no recommended metabolic biomarker to assess
response to treatment. Early treatment is encouraged
as soon as the diagnosis is considered, as some neuro-
logical deficits, in particular diaphragmatic paralysis,
may be irreversible. Once our patient started oral ribo-
flavin, she made a remarkable recovery in motor
function (see online supplementary file/video). Her
clinical improvement has been sustained for 3 years
with regular dietician input and a weaning dose of
maintenance riboflavin supplementation (minimum
200 mg daily).
Key points
▸ Brown–Vialetto–Van Laere syndrome syndrome is a
rare genetic neurological condition, often presenting
with subacute pontobulbar palsy on a background of
sensorineural deafness.
▸ Intervention with riboflavin and improved nutrition
can reverse potentially lethal motor weakness
leading to a sustained clinical recovery, highlighting
the importance of early diagnosis.
▸ Compound heterozygous mutations at the C-terminus
of the SLC52A3 gene may preserve partial riboflavin
transporter function and explain the late presentation
following dietary deficiency.
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Table 1 Characteristics of compound heterozygous mutations found in our patient in the SLC52A3 gene
Exon Nucleotide Amino acid change Reference Present in 900 controls Present in 150 sALS FATHMM prediction
5 c.1237 T>C p.V413A rs2676066871 No No Damaging
5 c.1381T>G p.D461Y rs140360713 No No Damaging
FATHMM, functional analysis through hidden Markov models (prediction software for the functional consequences of coding and non-coding variants);
sALS, sporadic amyotrophic lateral sclerosis.
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Ophthalmological assessment excluded optic atrophy.
A nutritional assessment of the weeks leading up to her
neurological decline identified a reduced intake of
riboflavin-rich foods, such as cereals and dairy pro-
ducts, as well as weight loss from 57 kg to 45 kg. Her
estimated dietary riboflavin intake (0.46–0.72 mg per
day) over this period was below the recommended
level (1.1 mg per day) for her age and sex.
Serum anti-ganglioside, anti-nicotinic acetylcholine
receptor, antinuclear and anti-neutrophil cytoplasmic
antibodies were all negative. MR scan of brain was
normal. Cerebrospinal fluid (CSF) analysis was normal
apart from a mildly elevated protein at 635 mg/L (250–
450). CSF viral, Lyme and oligoclonal band tests were
negative. Serum lead concentration was normal. Plasma
free carnitine, acylcarnitine and riboflavin levels were
normal but these assays were performed after she had
started treatment. DNA sequencing of the SLC52A3
gene found compound heterozygous mutations,
c.1237T>C/V413A and c.1381T>G/D461Y, in exon 5.
DIFFERENTIAL DIAGNOSIS
The initial differential diagnosis for her subacute lower
brainstem syndrome was broad. This included inflam-
matory (eg, Guillain–Barré/Miller Fisher syndrome),
infective (eg, Listeria or tuberculous meningitis), auto-
immune (myasthenia gravis) or toxic (botulism, lead)
causes.
TREATMENT
On admission, she was monitored in the High
Dependency Unit and received oxygen, intravenous
immunoglobulin, high-dose corticosteroids and nutri-
tional supplements via a nasogastric tube. Nineteen
days after admission, we made the clinical diagnosis of
BVVL and started high-dose oral riboflavin at
1200 mg/day, initially via nasogastric tube and subse-
quently via radiologically inserted gastrostomy.
OUTCOME AND FOLLOW-UP
Her motor functions steadily improved over 5 weeks
such that at discharge she could walk short distances
unaided with ankle–foot orthoses for bilateral foot
drop and mild weakness of her intrinsic hand
muscles. She was no longer breathless on mild exer-
tion and her lung function had improved (forced
vital capacity 2.44 L, 83% of predicted). Mild dys-
phonia and dysarthria persisted due to moderate
vocal cord and facial muscle paresis. She has
remained stable 3 years after the diagnosis, owing to
the continued riboflavin therapy (initially 400 mg
three times daily, slowly weaned to 200 mg daily)
and improved nutrition.
DISCUSSION
Clinical characteristics
The age of onset of BVVL is typically between infancy
and the third decade.2 3 Our patient presented in her
fourth decade, much older than the reported mean
age of presentation (4.1–8.2 years).3 4 The clinical
presentation is highly variable and, as well as the char-
acteristic features of lower cranial nerve involvement
(nerves VIII–XII), can include lower and upper motor
neurone limb signs, respiratory compromise, facial
weakness, sensory ataxia and optic atrophy.2 4 Half of
the cases are familial, arising with an autosomal reces-
sive pattern of inheritance with homozygous or com-
pound heterozygous mutations.
The riboflavin transporter genes
The underlying genetic cause of BVVL was identified in
2010. The first report described seven patients with
homozygous mutations and one compound heterozy-
gote affecting exons 2, 3 and 5 of the riboflavin trans-
porter gene SLC52A3 (aka C20orf54 or RFVT3).1 A
novel homozygous pathogenic mutation in a related
riboflavin transporter gene SLC52A2 (aka RFVT2) was
found in a Lebanese kindred.5 Further mutations in this
gene have subsequently been described in 18 child-onset
cases.6 Bosch et al4 have summarised the published
mutations in SLC52A2 and SLC52A3 up until 2012.
SLC52A2 and SLC52A3 genes code for the human
riboflavin transporters (RFVT) 2 and 3, respectively. A
third member of the family, SLC52A1 (coding for
RFVT1), has not yet been shown to harbour patho-
genic mutations in BVVL itself, but was abnormal in a
case of maternal riboflavin deficiency.7
Our patient was compound heterozygous for the
SLC52A3 gene (V413A/D461Y). This evolutionarily
conserved gene contains five exons and eleven pre-
dicted transmembrane helices.1 The V413A mutation
has previously been reported in a compound heterozy-
gous pattern. This patient had a milder phenotype,
manifested by disease onset in the second decade, an
initial presentation of peripheral neuropathy and
untreated survival into the sixth decade.
The D461Y mutation has been reported in 36
European ExAC samples in a heterozygous manner, but
has not been previously reported to cause BVVL. Its
pathogenicity is endorsed by its absence in 900 of our
screened controls and predicted ‘damaging’ effect using
FATHMM prediction software (see table 1). Thus, the
D461Y mutation, similar to other pathological
SLC52A3 mutations (eg, F457L, N21S), occurs at low
frequencies in the general European population in the
heterozygous state. We suggest that it causes BVVL
when either homozygous or, as in this case, compound
heterozygous with another known pathogenic variant.
Genotype–phenotype relationship
The clinical phenotypes related to SLC52A2
and SLC52A3 mutations are distinguishable. The
SLC52A2 mutation phenotype is associated with an
ataxic gait as the presenting symptom, with a higher
likelihood of sensorimotor neuropathy, optic atrophy,
weakness of the upper limbs and neck and late-
I IES
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2 and 3’, to reflect better the underlying patho-
aetiology and distinct clinical phenotypes in this
condition.4 6
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amino acid catabolism. This stems from an acquired
functional riboflavin deficiency, owing to defective ribo-
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tion in plasma riboflavin, flavin mononucleotide or
flavin adenine dinucleotide concentration, with an
abnormal plasma acylcarnitine profile (selective increase
in short- and medium-chain fatty acid plasma concentra-
tions).8 However, a recent report suggests only 58% of
genetically confirmed patients with BVVL had abnormal
acylcarnitine profiles.3 Additionally, urinary organic
acid profiles can resemble those seen in the multiple
acyl-CoA dehydrogenation defect.
Our patient developed symptoms after an abrupt
change in the quality of her diet 8 weeks before admis-
sion. This very likely triggered motor neuronal dys-
function and degeneration, as her genetic defect left
her vulnerable to a low dietary intake of riboflavin.
Riboflavin therapy in BVVL
The general management of patients with BVVL
includes supportive measures, such as nasogastric tube or
gastrostomy insertion to ensure adequate nutrition, and
non-invasive ventilation to overcome any neurogenic
respiratory compromise. Corticosteroids and immuno-
globulins do not help.2
Riboflavin treatment (reported dose range 7–60 mg/kg/
day) can normalise the metabolic abnormalities
detected in BVVL and lead to clinical stabilisation and
improvement in most people.3 4 9 10 Currently there is
no recommended metabolic biomarker to assess
response to treatment. Early treatment is encouraged
as soon as the diagnosis is considered, as some neuro-
logical deficits, in particular diaphragmatic paralysis,
may be irreversible. Once our patient started oral ribo-
flavin, she made a remarkable recovery in motor
function (see online supplementary file/video). Her
clinical improvement has been sustained for 3 years
with regular dietician input and a weaning dose of
maintenance riboflavin supplementation (minimum
200 mg daily).
Key points
▸ Brown–Vialetto–Van Laere syndrome syndrome is a
rare genetic neurological condition, often presenting
with subacute pontobulbar palsy on a background of
sensorineural deafness.
▸ Intervention with riboflavin and improved nutrition
can reverse potentially lethal motor weakness
leading to a sustained clinical recovery, highlighting
the importance of early diagnosis.
▸ Compound heterozygous mutations at the C-terminus
of the SLC52A3 gene may preserve partial riboflavin
transporter function and explain the late presentation
following dietary deficiency.
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ducts, as well as weight loss from 57 kg to 45 kg. Her
estimated dietary riboflavin intake (0.46–0.72 mg per
day) over this period was below the recommended
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phonia and dysarthria persisted due to moderate
vocal cord and facial muscle paresis. She has
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the continued riboflavin therapy (initially 400 mg
three times daily, slowly weaned to 200 mg daily)
and improved nutrition.
DISCUSSION
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and the third decade.2 3 Our patient presented in her
fourth decade, much older than the reported mean
age of presentation (4.1–8.2 years).3 4 The clinical
presentation is highly variable and, as well as the char-
acteristic features of lower cranial nerve involvement
(nerves VIII–XII), can include lower and upper motor
neurone limb signs, respiratory compromise, facial
weakness, sensory ataxia and optic atrophy.2 4 Half of
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SLC52A2 and SLC52A3 genes code for the human
riboflavin transporters (RFVT) 2 and 3, respectively. A
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RFVT1), has not yet been shown to harbour patho-
genic mutations in BVVL itself, but was abnormal in a
case of maternal riboflavin deficiency.7
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SLC52A3 gene (V413A/D461Y). This evolutionarily
conserved gene contains five exons and eleven pre-
dicted transmembrane helices.1 The V413A mutation
has previously been reported in a compound heterozy-
gous pattern. This patient had a milder phenotype,
manifested by disease onset in the second decade, an
initial presentation of peripheral neuropathy and
untreated survival into the sixth decade.
The D461Y mutation has been reported in 36
European ExAC samples in a heterozygous manner, but
has not been previously reported to cause BVVL. Its
pathogenicity is endorsed by its absence in 900 of our
screened controls and predicted ‘damaging’ effect using
FATHMM prediction software (see table 1). Thus, the
D461Y mutation, similar to other pathological
SLC52A3 mutations (eg, F457L, N21S), occurs at low
frequencies in the general European population in the
heterozygous state. We suggest that it causes BVVL
when either homozygous or, as in this case, compound
heterozygous with another known pathogenic variant.
Genotype–phenotype relationship
The clinical phenotypes related to SLC52A2
and SLC52A3 mutations are distinguishable. The
SLC52A2 mutation phenotype is associated with an
ataxic gait as the presenting symptom, with a higher
likelihood of sensorimotor neuropathy, optic atrophy,
weakness of the upper limbs and neck and late-
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